An online platform that offers public and private companies, across multiple industries the ability to stay active and engaged with the investment community.
Dr. Toufic Kachaamy, Chief of Medicine at City of Hope Phoenix, joins a #WhatThisMeans segment to discuss the clinical significance of $AMIX’s data presented at the SSO Annual Meeting and its selection for a podium presentation.
🔗: https://t.co/Pqr6PuEUpL
#MedTech
In a #WhatThisMeans segment, Tom Equels, Dr. Charles Lapp and Dr. Christopher Nicodemus, examine current Ebola outbreak concerns, the unmet need surrounding the Bundibugyo strain, and Ampligen’s previously published antiviral research.
🔗: https://t.co/ggmYEojLQQ
$AIM #Ebola
In a #WhatThisMeans segment, Walter Klemp, CEO of $MBRX, discusses the enrollment of the 45th subject in Moleculin’s pivotal Phase 2B/3 MIRACLE trial evaluating AnnAraC for relapsed or refractory AML.
🔗Watch here: https://t.co/I6eaupFPUq
📅 Mark Your Calendar
enVVeno Medical will take part in a #VirtualInvestor Closing Bell segment on June 9 at 4 PM ET. Tune in to hear key updates from CEO Robert Berman.
Register Here: https://t.co/qIjar17vVo
$NVNO #VenousDisease#DeepVenousInsufficiency#CVI#CVD
In a #VirtualInvestor “What This Means” segment, @akaritx CEO Abizer Gaslightwala discusses the Company’s first ASCO abstract acceptance and preclinical KRAS synergy data supporting its differentiated ADC platform.
Watch here: https://t.co/V2zrm2bNct
$AKTX #ASCO#Oncology
In a #VirtualInvestor#KOLConnect segment, Dr. Elena Ratner discusses the unmet need in ovarian cancer, immunologically “cold” tumors, and Ernexa’s differentiated off-the-shelf cell therapy approach.
🔗https://t.co/UY4fw4Z4hu
$ERNA @ernexatx
In a #VirtualInvestor#CEOConnect segment, Rami Levin highlights the Company’s recent strategic transformation progress, including its $22.5 million financing and pipeline development strategy focused on long-term shareholder value creation.
🔗: https://t.co/cTPaYafuSe
$CNSP
@AimImmuno In a #KOLConnect segment, Professor Dr. Casper H.J. van Eijck joins CEO Tom Equels to discuss Ampligen’s potential in late-stage pancreatic cancer, highlighting its mechanism of action, clinical data, development strategy, and key regulatory milestones.
In a #KOLConnect segment, Professor Dr. Casper H.J. van Eijck joins CEO Tom Equels to discuss Ampligen’s potential in late-stage pancreatic cancer, highlighting its mechanism of action, clinical data, development strategy, and key regulatory milestones.
https://t.co/w3RJJ78tqX
🔔 Live Today at 4 PM ET!
Catch @ernexatx live in their #VirtualInvestor Closing Bell segment for the latest corporate updates, key progress highlights, and a look at upcoming initiatives.
Watch live here: https://t.co/bCvN1jowe7
$ERNA #CancerResearch#DeliveringHope
⏰ Happening Tomorrow at 4 PM ET
Join CEO Sanjeev Luther live as he discusses the latest updates from $ERNA during a #VirtualInvestor Closing Bell session. Be sure to tune in!
Don't miss it: https://t.co/bCvN1jowe7
#CancerResearch#DeliveringHope@ernexatx
@enVVenoMedical joined a #WhatThisMeans segment to discuss the FDA’s first-ever IDE approval for a U.S. pivotal study evaluating a non-surgical replacement venous valve and what this could mean for the ~3 million U.S. patients suffering from DVI.
🔗: https://t.co/Mx3HIq3eJO
Virtual Investor KOL Connect: @ErnexaTx features CSO, Dr. Pierce, to discuss the ovarian cancer landscape, unmet need and the potential of their lead development asset to address limitations.
🔴 Starting Now!
$AREC is live in the #VirtualInvestor CEO Connect.
Hear from CEO Mark Jensen and join the live Q&A.
Join now: https://t.co/uAIioc9Mm7
#RareEarths#SupplyChain
Tune in Today!
$AREC will be featured in the #VirtualInvestor CEO Connect at 10 AM ET.
Hear from CEO Mark Jensen, followed by a live Q&A.
Join here: https://t.co/uAIioc9Mm7
#RareEarths#SupplyChain